Ann: Exopharm Gains US Patent for LEAP Technology, page-14

It goes without saying that locking in deals will be critical to investor confidence and share price growth. We're dependent on one to avoid another dilutive CR in the next 12 months.

My 2 cents is that a deal (or deals) is imminent - hence the recent uptick in people investment (i.e. 2x Senior Executives to drive deal closure and ensure new partnerships are commercially sound, plus a new researcher focused on in-house development of exosome drugs).

I'm also observing quite a few exosome-focused researcher positions opening up at universities across the world. There seems to be an 'arms race' to advance understanding of exosomes and develop a portfolio of therapeutics.